Scientists can now buy the direct-to-consumer sequencing product, and research participants can join 23andMe’s database.

The personal genomics firm is ramping up its suite of disease-related genetic tests.

The genomic entrepreneur has struck a deal with a South African health insurer to sequence the exomes of its customers.

Some doctors advise shoppers to be skeptical of a newly marketed cancer diagnostic.

With $100 million in initial funding, Helix aims to make personal genomics accessible.

The personal genomics firm announces plans to make medicines.

The US Food and Drug Administration will allow the personal genomics company to resume a disease-risk analysis.

The personal genomics company strikes yet another deal to glean biomedically relevant information from its user data.

British consumers can buy the genetic testing-associated health prediction service forbidden by the US government.

Until health care becomes truly personalized, race and ethnicity will continue to be important clues guiding medical treatments.

Illumina says its newest sequencing system can churn out whole human genomes for $1,000 apiece.

Another personal genomics company faces government pressure—this time from the Federal Trade Commission.

January 2014's selection of notable quotes

The company announces that it will stop offering health interpretations of personal genetic data.

Shortly after getting in trouble with the Food and Drug Administration, the personal genetic testing company is slapped with a class action lawsuit.

The US Food and Drug Administration blocks the marketing of unapproved genetic tests.  

23andMe denies that its new patent will be used to help couples create designer babies based on personal genetic testing.

Science gets personal as researchers—professional and amateur—plumb the depths of their own molecular biology.

Meet Larry Smarr, a UC San Diego computer scientist who records several facets of his physiology, on the hunt for signs of present or future health problems.